Veru Inc. Earnings Recaps
Q1 2026
Feb 11, 2026
Veru Inc. delivered a robust performance in Q1 FY2026, marked by significant progress in its clinical trials and regulatory developments for its obesity treatment candidates, Novosarm and cabozantinib.
Key takeaways
- The Phase 2b clinical trial for Novosarm demonstrated proof of concept for selective fat loss while preserving lean mass in older patients, a critical advancement in obesity treatment.
- Regulatory discussions with the FDA confirmed two potential pathways for approval, enhancing the strategic outlook for Novosarm in combination with GLP-1 receptor agonists.
- The FDA's recent acknowledgment of bone mineral density as a validated surrogate endpoint could open new opportunities for Novosarm’s development in postmenopausal women with obesity and osteoporosis.
- Veru continues to address challenges in GLP-1 treatments, with Novosarm potentially providing solutions for patients who experience weight loss plateaus on current therapies.
Q3 2025
Aug 12, 2025
Veru Inc. reported promising results from its Phase 2b clinical trial for Inovasaram, demonstrating effective preservation of lean mass while enhancing fat loss in older patients using semaglutide for weight management.
Key takeaways
- Inovasaram treatment in conjunction with semaglutide achieved 100% preservation of lean mass, significantly outperforming the placebo group (p < 0.001).
- Participants receiving Inovasaram exhibited a dose-dependent fat loss, with the six mg group achieving a 42% greater reduction compared to the placebo (p = 0.017).
- The safety profile of the Inovasaram and semaglutide combination was confirmed, with positive results seen during the maintenance extension phase, indicating reduced weight regain post-treatment.
- After discontinuation of semaglutide, the three mg Inovasaram significantly limited weight regain by 46% compared to the placebo, highlighting its potential for long-term weight management.